{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:29Z","timestamp":1790790269115,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":939,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["21K08131"],"award-info":[{"award-number":["21K08131"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08131"],"award-info":[{"award-number":["21K08131"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tafamidis improves prognosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). However, real-world data on the therapeutic effect of tafamidis are lacking. This study aimed to evaluate the clinical course, outcomes, and effectivity monitoring of the therapeutic effect of tafamidis in patients with ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This is a single-centre, retrospective observational study. We evaluated the clinical characteristics and outcomes in 125 consecutive patients with wild-type ATTR-CM (ATTRwt-CM) treated with tafamidis (treatment group) and 55 untreated patients (treatment-na\u00efve group). We monitored the therapeutic effect of tafamidis for 12 months by evaluating serial cardiac biomarker and imaging findings. The treatment group had significantly more favourable outcome in all-cause mortality and hospitalization due to heart failure than the treatment-na\u00efve group in both the entire cohort (P &amp;lt; 0.01) and the propensity score-matched cohort (P &amp;lt; 0.05). Kaplan\u2013Meier survival curves showed that tafamidis treatment significantly reduced all-cause mortality (P = 0.03, log-rank test), with the curves diverging after approximately 18 months of treatment in the propensity score-matched cohort. On inverse probability of treatment weighting analysis, tafamidis treatment showed a reduced all-cause mortality [hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.11\u20130.93; P = 0.04]. High-sensitivity cardiac troponin T (hs-cTnT) &amp;gt; 0.05 ng\/mL, B-type natriuretic peptide (BNP) &amp;gt; 250 pg\/mL, and estimated glomerular filtration rate (eGFR) &amp;lt; 45 mL\/min\/1.73 m2 scored 1 point each. Multivariate logistic regression analysis revealed that a high score (2\u20133 points) was a significantly poor prognostic factor of composite clinical outcomes, including all-cause death and hospitalization for heart failure (HR, 1.55; 95% CI, 1.22\u20131.98; P &amp;lt; 0.01) for patients in the treatment group. After 12 months of tafamidis treatment, hs-cTnT levels decreased significantly [0.054 (0.036\u20130.082) vs. 0.044 (0.033\u20130.076); P = 0.002], with no significant changes in BNP levels, echocardiographic parameters, native T1 value, and extracellular volume fraction on cardiac magnetic resonance imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prognosis of patients with ATTRwt-CM treated with tafamidis was more favourable than that of untreated patients. Patient stratification combined with biomarkers (hs-cTnT, BNP, and eGFR) predicted clinical outcomes. hs-cTnT may be a useful biomarker for evaluating the therapeutic effect of tafamidis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14380","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T01:50:50Z","timestamp":1681869050000},"page":"2319-2329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"10","author":[{"given":"Seiji","family":"Takashio","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Oike","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Usuku","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kidoh","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Kumamoto, 860-8556 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"2026012114090557000_ehf214380-bib-0001","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jjcc.2017.10.003","article-title":"Recent advances in diagnosis and treatment of cardiac amyloidosis","volume":"71","author":"Izumiya","year":"2018","journal-title":"J Cardiol"},{"key":"2026012114090557000_ehf214380-bib-0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026012114090557000_ehf214380-bib-0003","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114090557000_ehf214380-bib-0004","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ehf2.12884","article-title":"Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"7","author":"Yamada","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012114090557000_ehf214380-bib-0006","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114090557000_ehf214380-bib-0007","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114090557000_ehf214380-bib-0008","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114090557000_ehf214380-bib-0009","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114090557000_ehf214380-bib-0010","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026012114090557000_ehf214380-bib-0011","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114090557000_ehf214380-bib-0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114090557000_ehf214380-bib-0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1253\/circj.CJ-19-0811","article-title":"A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Endo","year":"2019","journal-title":"Circ J"},{"key":"2026012114090557000_ehf214380-bib-0014","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/ehf2.13847","article-title":"A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"9","author":"Nakashima","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0017","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"},{"key":"2026012114090557000_ehf214380-bib-0018","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1067\/mhl.2002.124554","article-title":"Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease","volume":"31","author":"Bennett","year":"2002","journal-title":"Heart Lung"},{"key":"2026012114090557000_ehf214380-bib-0019","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114090557000_ehf214380-bib-0020","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114090557000_ehf214380-bib-0021","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","article-title":"Cardiac magnetic resonance T1 mapping in cardiac amyloidosis","volume":"11","author":"Duca","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114090557000_ehf214380-bib-0022","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ehf2.12382","article-title":"Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy","volume":"6","author":"Shintani","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024717","article-title":"Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy","volume":"11","author":"Morioka","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012114090557000_ehf214380-bib-0024","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2010.06.016","article-title":"Troponin elevation in heart failure prevalence, mechanisms, and clinical implications","volume":"56","author":"Kociol","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114090557000_ehf214380-bib-0026","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacc.2013.03.065","article-title":"Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure","volume":"62","author":"Takashio","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114090557000_ehf214380-bib-0027","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012114090557000_ehf214380-bib-0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/000331970105200407","article-title":"Cardiac amyloidosis presenting as microvascular angina","volume":"52","author":"Ogawa","year":"2001","journal-title":"Angiology"},{"key":"2026012114090557000_ehf214380-bib-0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41598-018-37230-1","article-title":"Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers","volume":"9","author":"Dasari","year":"2019","journal-title":"Sci Rep"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2319\/64704786\/eschf_10_4_2319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2319\/64704786\/eschf_10_4_2319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:09:45Z","timestamp":1769022585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/4\/2319\/8285314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,18]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14380","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}